<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36803843</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis.</ArticleTitle><Pagination><StartPage>26</StartPage><MedlinePgn>26</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">26</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03010-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Systemic lupus erythematosus (SLE) is heterogeneous in organ involvement and disease severity, presenting a broad clinical phenotype. Systemic type I interferon (IFN) activity has been shown to be associated with lupus nephritis, autoantibodies, and disease activity in treated SLE patients; however, these relationships are unknown in treatment-naive patients. We aimed to determine the relationship of systemic IFN activity with clinical phenotypes, disease activity, and damage accrual in treatment-naive SLE patients before and after induction and maintenance therapy.</AbstractText><AbstractText Label="METHODS">Forty treatment-naive SLE patients were enrolled for this retrospective longitudinal observational study to examine the relationship between serum IFN activity and clinical manifestations of EULAR/ACR-2019 criteria domains, disease activity measures, and damage accrual. As controls, 59 other treatment-naive rheumatic disease patients and 33 healthy individuals were recruited. Serum IFN activity was measured by WISH bioassay and presented as an IFN activity score.</AbstractText><AbstractText Label="RESULTS">Treatment-naive SLE patients had significantly higher serum IFN activity than other rheumatic disease patients (score: 97.6 and 0.0, respectively, p &lt; 0.001). High serum IFN activity was significantly associated with fever, hematologic disorders (leukopenia), and mucocutaneous manifestations (acute cutaneous lupus and oral ulcer) of EULAR/ACR-2019 criteria domains in treatment-naive SLE patients. Serum IFN activity at baseline significantly correlated with SLEDAI-2K scores and decreased along with a decrease in SLEDAI-2K scores after induction and maintenance therapy (R<sup>2</sup> = 0.112, p = 0.034). SLE patients who developed organ damage (SDI &#x2265; 1) had higher serum IFN activity at baseline than those who did not (SDI = 0) (150.0 versus 57.3, p= 0.018), but the multivariate analysis did not detect its independent significance (p = 0.132).</AbstractText><AbstractText Label="CONCLUSIONS">Serum IFN activity is characteristically high and is linked to fever, hematologic disorders, and mucocutaneous manifestations in treatment-naive SLE patients. Serum IFN activity at baseline correlates with disease activity and decreases in parallel with a decrease in disease activity after induction and maintenance therapy. Our results suggest that IFN plays an important role in the pathophysiology of SLE and that serum IFN activity at baseline may be a potential biomarker for the disease activity in treatment-naive SLE patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Miyachi</LastName><ForeName>Kazusa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Iwamoto</LastName><ForeName>Taro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. iwamototaro0725@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Shotaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ida</LastName><ForeName>Tomoaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mimura</LastName><ForeName>Norihiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furuta</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niewold</LastName><ForeName>Timothy B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital for Special Surgery, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Clinical manifestation</Keyword><Keyword MajorTopicYN="N">Damage accrual</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Type I interferon</Keyword></KeywordList><CoiStatement>KI has received research grants from Mitsubishi-Tanabe Pharma and has received honoraria for lectures from Abbvie, Mitsubishi-Tanabe Pharma, Eli Lilly Japan, Novartis, Pfizer Japan, Janssen Pharmaceutical, Eisai, Gilead Sciences and Bristol Myers Squibb, all unrelated to the current manuscript. HN has received research grants from Chugai Pharmaceutical, Abbvie, Takeda Pharmaceutical, Astellas Pharma, Eli Lilly Japan, Asahikasei Pharma, Pfizer Japan, UCB Japan, Eizai, Mitsubishi Tanabe Pharma and Bristol Myers Squibb, and has received honoraria for lectures from Chugai Pharmaceutical, Abbvie, Takeda Pharmaceutical, Astellas Pharma, Eli Lilly Japan, Asahikasei Pharma, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Eisai, Bristol Myers Squibb and Nippon Kayaku, all unrelated to the current manuscript. The other authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>21</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36803843</ArticleId><ArticleId IdType="pmc">PMC9936752</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03010-0</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03010-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716&#x2013;730. doi: 10.1038/nrrheum.2016.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nived O, J&#xf6;nsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol. 2002;29:1398&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136895</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstr&#xf8;m K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958&#x2013;967. doi: 10.1136/annrheumdis-2013-205139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol. 2014;26:467&#x2013;474. doi: 10.1097/BOR.0000000000000087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000087</ArticleId><ArticleId IdType="pmc">PMC4280994</ArticleId><ArticleId IdType="pubmed">25010440</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK, et al. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492&#x2013;502. doi: 10.1038/sj.gene.6364408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6364408</ArticleId><ArticleId IdType="pmc">PMC2702174</ArticleId><ArticleId IdType="pubmed">17581626</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008;58:2113&#x2013;2119. doi: 10.1002/art.23619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23619</ArticleId><ArticleId IdType="pmc">PMC2729701</ArticleId><ArticleId IdType="pubmed">18576315</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008;58:2481&#x2013;2487. doi: 10.1002/art.23613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23613</ArticleId><ArticleId IdType="pmc">PMC2621107</ArticleId><ArticleId IdType="pubmed">18668568</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloum R, Franek BS, Kariuki SN, Rhee L, Mikolaitis RA, Jolly M, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010;62:553&#x2013;561. doi: 10.1002/art.27182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27182</ArticleId><ArticleId IdType="pmc">PMC2832192</ArticleId><ArticleId IdType="pubmed">20112359</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012;71:463&#x2013;468. doi: 10.1136/annrheumdis-2011-200463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2011-200463</ArticleId><ArticleId IdType="pmc">PMC3307526</ArticleId><ArticleId IdType="pubmed">22088620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987;70:562&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1542177</ArticleId><ArticleId IdType="pubmed">2449306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9:664&#x2013;671. doi: 10.1191/096120300674499064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300674499064</ArticleId><ArticleId IdType="pubmed">11199920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711&#x2013;723. doi: 10.1084/jem.20021553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021553</ArticleId><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610&#x2013;2615. doi: 10.1073/pnas.0337679100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491&#x2013;1503. doi: 10.1002/art.21031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21031</ArticleId><ArticleId IdType="pubmed">15880830</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:2951&#x2013;2962. doi: 10.1002/art.22044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22044</ArticleId><ArticleId IdType="pubmed">16947629</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon-&#x3b1; activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63:1044&#x2013;1053. doi: 10.1002/art.30187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30187</ArticleId><ArticleId IdType="pmc">PMC3068224</ArticleId><ArticleId IdType="pubmed">21162028</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Gunnarsson I, Dorschner J, Eketj&#xe4;ll S, Zickert A, Niewold TB, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21:107. doi: 10.1186/s13075-019-1878-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto T, Dorschner JM, Selvaraj S, Mezzano V, Jensen MA, Vsetecka D, et al. High systemic type I interferon activity is associated with active class III/IV lupus nephritis. J Rheumatol. 2022;49:388&#x2013;397. doi: 10.3899/jrheum.210391.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210391</ArticleId><ArticleId IdType="pmc">PMC8977285</ArticleId><ArticleId IdType="pubmed">34782453</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022;81:951&#x2013;961. doi: 10.1136/annrheumdis-2021-221425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017;214:1547&#x2013;1555. doi: 10.1084/jem.20161451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20161451</ArticleId><ArticleId IdType="pmc">PMC5413335</ArticleId><ArticleId IdType="pubmed">28420733</ArticleId></ArticleIdList></Reference><Reference><Citation>Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14:214&#x2013;228. doi: 10.1038/nrrheum.2018.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2018.31</ArticleId><ArticleId IdType="pmc">PMC6625751</ArticleId><ArticleId IdType="pubmed">29559718</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European league against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151&#x2013;1159. doi: 10.1136/annrheumdis-2018-214819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271&#x2013;1277. doi: 10.1002/art.1780251101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569&#x2013;2581. doi: 10.1002/art.27584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27584</ArticleId><ArticleId IdType="pubmed">20872595</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747&#x2013;1755. doi: 10.1136/annrheumdis-2013-204424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204424</ArticleId><ArticleId IdType="pubmed">24092682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1&#x2013;11. doi: 10.1002/art.37715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37715</ArticleId><ArticleId IdType="pubmed">23045170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241&#x2013;250. doi: 10.1097/01.ASN.0000108969.21691.5D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASN.0000108969.21691.5D</ArticleId><ArticleId IdType="pubmed">14747370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363&#x2013;369. doi: 10.1002/art.1780390303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8:685&#x2013;691. doi: 10.1191/096120399680411281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399680411281</ArticleId><ArticleId IdType="pubmed">10568907</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorbaugh J, Samanta T, Bright SW, Sissons SE, Chang CY, Oberoi P, et al. Measurement of IL-21 in human serum and plasma using ultrasensitive MSD S-PLEX and Quanterix SiMoA methodologies. J Immunol Methods. 2019;466:9&#x2013;16. doi: 10.1016/j.jim.2018.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2018.12.005</ArticleId><ArticleId IdType="pubmed">30590020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006;54:1906&#x2013;1916. doi: 10.1002/art.21890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21890</ArticleId><ArticleId IdType="pubmed">16736505</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029&#x2013;2036. doi: 10.1136/ard.2011.150326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2011.150326</ArticleId><ArticleId IdType="pubmed">21803750</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganser A, Carlo-Stella C, Greher J, V&#xf6;lkers B, Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood. 1987;70:1173&#x2013;1179. doi: 10.1182/blood.V70.4.1173.1173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V70.4.1173.1173</ArticleId><ArticleId IdType="pubmed">3115335</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26:112S&#x2013;121S. doi: 10.1002/hep.510260720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.510260720</ArticleId><ArticleId IdType="pubmed">9305675</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012;166:971&#x2013;975. doi: 10.1111/j.1365-2133.2012.10825.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2012.10825.x</ArticleId><ArticleId IdType="pmc">PMC3336025</ArticleId><ArticleId IdType="pubmed">22242767</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129:1359&#x2013;1371. doi: 10.1172/JCI124466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124466</ArticleId><ArticleId IdType="pmc">PMC6391094</ArticleId><ArticleId IdType="pubmed">30645203</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Alase A, Antanaviciute A, Carr IM, Md Yusof MY, Wittmann M, et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun. 2020;11:6149. doi: 10.1038/s41467-020-19918-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19918-z</ArticleId><ArticleId IdType="pmc">PMC7708979</ArticleId><ArticleId IdType="pubmed">33262343</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022;18:575&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">36097207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender R, Lange S. Adjusting for multiple testing--when and how? J Clin Epidemiol. 2001;54:343&#x2013;349. doi: 10.1016/S0895-4356(00)00314-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(00)00314-0</ArticleId><ArticleId IdType="pubmed">11297884</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto T, Niewold TB. Genetics of human lupus nephritis. Clin Immunol. 2017;185:32&#x2013;39. doi: 10.1016/j.clim.2016.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.09.012</ArticleId><ArticleId IdType="pmc">PMC5373939</ArticleId><ArticleId IdType="pubmed">27693588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T, et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol. 2014;25:2859&#x2013;2870. doi: 10.1681/ASN.2013050446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2013050446</ArticleId><ArticleId IdType="pmc">PMC4243339</ArticleId><ArticleId IdType="pubmed">24925725</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheum. 2014;66:390&#x2013;396. doi: 10.1002/art.38220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38220</ArticleId><ArticleId IdType="pmc">PMC4002759</ArticleId><ArticleId IdType="pubmed">24504811</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vgren T, Eloranta ML, B&#xe5;ve U, Alm GV, R&#xf6;nnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50:1861&#x2013;1872. doi: 10.1002/art.20254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20254</ArticleId><ArticleId IdType="pubmed">15188363</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009;18:980&#x2013;989. doi: 10.1177/0961203309105529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309105529</ArticleId><ArticleId IdType="pmc">PMC4752166</ArticleId><ArticleId IdType="pubmed">19762399</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose T, Gr&#xfc;tzkau A, Klotsche J, Enghard P, Flechsig A, Keller J, et al. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology (Oxford) 2017;56:1618&#x2013;1626. doi: 10.1093/rheumatology/kex220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex220</ArticleId><ArticleId IdType="pubmed">28859328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, O&#x2019;Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74:1706&#x2013;1713. doi: 10.1136/annrheumdis-2013-205171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205171</ArticleId><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessler BJ, Alarcon GS, McGwin G, Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473&#x2013;1480. doi: 10.1002/art.21039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21039</ArticleId><ArticleId IdType="pubmed">15880829</ArticleId></ArticleIdList></Reference><Reference><Citation>Billi AC, Ma F, Plazyo O, Gharaee-Kermani M, Wasikowski R, Hile GA, et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci Transl Med. 2022;14:eabn2263. doi: 10.1126/scitranslmed.abn2263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn2263</ArticleId><ArticleId IdType="pmc">PMC9169615</ArticleId><ArticleId IdType="pubmed">35476593</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel J, Vazquez T, Chin F, Keyes E, Yan D, Diaz D, et al. Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient response to antimalarials. Arthritis Rheum. 2022;74:1687&#x2013;1698. doi: 10.1002/art.42235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42235</ArticleId><ArticleId IdType="pubmed">35583812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>